Patents Assigned to The United States of America as represented by Secretary of the Department of Health and Human Services
-
Publication number: 20240192226Abstract: Kits and methods to distinguish between false and true labor are provided. The kits and methods can utilize differences in abundance and/or differences in the rate of change in abundance of B7-H2, SORC2, TF, C1-Esterase Inhibitor, Ran, IMDH1 and/or PGAM1, as markers of true labor.Type: ApplicationFiled: January 16, 2024Publication date: June 13, 2024Applicants: Wayne State University, The United States of America, as Represented by the Secretary, Department of Health & Human ServicesInventors: Adi L. Tarca, Piya Chaemsaithong, Tinnakorn Chaiworapongsa, Sonia S. Hassan, Roberto Romero
-
Publication number: 20240191284Abstract: The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.Type: ApplicationFiled: February 27, 2024Publication date: June 13, 2024Applicants: The Children's Medical Center Corporation, The United States of America, As Represented by the Secretary, Department of Health & Human ServicesInventors: Anjana Rao, Mamta Tahiliani, Kian Peng Koh, Suneet Agarwal, Aravind Iyer
-
Patent number: 12005115Abstract: Vaccines are provided that elicit neutralizing antibodies to Epstein-Barr virus (EBV). Some vaccines comprise nanoparticles that display envelope proteins from EBV on their surface. The nanoparticles comprise fusion proteins comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to at least a portion of an EBV envelope protein. The fusion proteins self-assemble to form the envelope protein-displaying nanoparticles. Such vaccines can be used to vaccinate an individual against infection by different types of Epstein-Barr viruses as well as Epstein-Barr viruses that are antigenically divergent from the virus from which the EBV envelope protein was obtained. Also provided are fusion proteins and nucleic acid molecules encoding such proteins.Type: GrantFiled: July 7, 2020Date of Patent: June 11, 2024Assignee: The United States of America as Represented By The Secretary of the Department of Health and Human ServicesInventors: Masaru Kanekiyo, Gary J. Nabel, Jeffrey Cohen, Wei Bu
-
Publication number: 20240181038Abstract: The present invention relates to a carrier-formulated mRNA comprising at least one coding sequence encoding an influenza HA stem polypeptide, and to related aspects.Type: ApplicationFiled: March 25, 2022Publication date: June 6, 2024Applicants: GLAXOSMITHKLINE BIOLOGICALS SA, UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Ventzislav Bojidarov VASSILEV, Corey MALLETT, Ronan ROUXEL, Normand BLAIS, Masaru KANEKIYO, Barney S. GRAHAM
-
Patent number: 11999796Abstract: The invention provides a chimeric antigen receptor (CAR) having antigenic specificity for CD70, the CAR comprising: an antigen binding—transmembrane domain comprising a CD27 amino acid sequence lacking all or a portion of the CD27 intracellular T cell signaling domain; a 4-1BB intracellular T cell signaling domain; a CD3? intracellular T cell signaling domain; and optionally, a CD28 intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: GrantFiled: June 19, 2020Date of Patent: June 4, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Qiong J. Wang, Zhiya Yu, James C. Yang
-
Patent number: 11992523Abstract: The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases.Type: GrantFiled: June 27, 2022Date of Patent: May 28, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Gary J. Nabel, Wataru Akahata, Srinivas Rao
-
Patent number: 11992519Abstract: A chimeric antigen receptor is disclosed that includes: (a) an scFv comprising a light chain variable domain (VL) and a heavy chain variable domain (VH), wherein the scFv specifically binds to CCR4; (b) a hinge and transmembrane domain from CD8; (c) an intracellular 4-1BB signaling domain; and (d) an intracellular CD3 zeta signaling domain, wherein (a)-(d) are in N to C terminal order. Uses of the chimeric antigen receptor, such as for treating a malignancy, are also disclosed.Type: GrantFiled: June 21, 2021Date of Patent: May 28, 2024Assignees: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services, The United States Government as represented by the Department of Veterans AffairsInventors: Liyanage Parakrama Perera, Thomas Alexander Waldmann, Kevin Charles Conlon, Pin-Yu Perera
-
Publication number: 20240165153Abstract: An aspect of the invention provides nucleic acids comprising a nucleotide sequence encoding chimeric antigen receptor (CAR) amino acid constructs. Polypeptides, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CAR constructs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: ApplicationFiled: March 23, 2022Publication date: May 23, 2024Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: James N. Kochenderfer, Norris Lam
-
Publication number: 20240166637Abstract: The present invention is related to the development of novel compounds and methods for the treatment and/or prevention of malaria. The compounds prevent the formation by the malaria parasite of the plasmodium surface anion channel (PSAC) on the surface of the host cell. The compounds and methods described herein are effective against infection by a wide variety of Plasmodia strains known as the causative agent of malaria.Type: ApplicationFiled: January 21, 2022Publication date: May 23, 2024Applicants: Microbiotix, Inc., The United States Of America As Represented By The Secretary, Department of Health and Human ServiceInventors: Samanthi L. Waidyarachchi, Son T. Nguyen, Xiaoyuan Ding, Sharmila Adhikari, John D. Williams, Norton P. Peet, Zachary D. Aron, Sanjay A. Desai, Michelle M. Butler
-
Publication number: 20240165224Abstract: The present invention relates to influenza virus immunisation using at least one influenza HA stem polypeptide in conjunction with squalene emulsion adjuvants, and to related aspects.Type: ApplicationFiled: March 25, 2022Publication date: May 23, 2024Applicants: GLAXOSMITHKLINE BIOLOGICALS SA, UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Ventzislav Bojidarov VASSILEV, Corey MALLETT, Ronan ROUXEL, Normand BLAIS, Masaru KANEKIYO, Barney S. GRAHAM
-
Patent number: 11987599Abstract: Disclosed herein are embodiments of a solid support suitable for synthesizing nucleic acid sequences. The solid support may have a structure according to Formula I, where CPG is controlled pore glass, and m, n, x, y, R1 and R2 are as defined herein. Also disclosed are methods for making and using the solid support, kits including solid support, and a universal linker phosphoramidite suitable for use in the solid support.Type: GrantFiled: June 28, 2021Date of Patent: May 21, 2024Assignee: United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Serge L. Beaucage, Andrzej M. Grajkowski
-
Patent number: 11980640Abstract: An embodiment of the invention provides bicistronic chimeric antigen receptor (CAR) amino acid constructs. Nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CAR constructs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed. Methods of making the CAR constructs are disclosed.Type: GrantFiled: May 15, 2018Date of Patent: May 14, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Haiying Qin, Crystal L Mackall, Terry J. Fry
-
Patent number: 11981707Abstract: Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.Type: GrantFiled: September 11, 2023Date of Patent: May 14, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter D. Kwong, Barney S. Graham, Jason S. McLellan, Jeffrey Boyington, Lei Chen, Man Chen, Gwo-Yu Chuang, Ivelin Stefanov Georgiev, Jason Gorman, Michael Gordon Joyce, Masaru Kanekiyo, Gilad Ofek, Marie Pancera, Mallika Sastry, Cinque Soto, Sanjay Srivatsan, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Tongqing Zhou
-
Publication number: 20240150290Abstract: Disclosed are compounds for treating or preventing a disease or disorder responsive to antagonism of a P2Y14R receptor agonist in a mammal in need thereof, for example, compounds of formulas (I) and (II), wherein R1-R8, X, Y, Z, X?, Y?, Z?, and A are as defined herein, that are useful in treating an inflammatory such as asthma, cystic fibrosis, and sterile inflammation of the kidney.Type: ApplicationFiled: January 5, 2022Publication date: May 9, 2024Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Kenneth A. Jacobson, Young-Hwan Jung, Zhiwei Wen
-
Patent number: 11976109Abstract: Antibodies and antigen binding fragments that specifically bind to ebolavirus glycoprotein and neutralize ebolavirus infection are disclosed. Nucleic acids encoding these antibodies, vectors, and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit an ebolavirus infection in a subject.Type: GrantFiled: December 31, 2018Date of Patent: May 7, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Nancy Sullivan, Kendra Leigh, John Misasi, Alberto Cagigi
-
Patent number: 11976299Abstract: Disclosed are methods of preparing an isolated population of dendritic cells, isolated populations of dendritic cells prepared by the methods, and pharmaceutical compositions comprising the isolated population of dendritic cells. Also disclosed are methods of treating or preventing cancer using the isolated population of dendritic cells or pharmaceutical compositions.Type: GrantFiled: September 18, 2017Date of Patent: May 7, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Gal Cafri, Paul F. Robbins, Jared J. Gartner, Steven A. Rosenberg
-
Patent number: 11975063Abstract: Recombinant chimeric bovine/human parainfluenza virus 3 (rB/HPIV3) vectors expressing Respiratory Syncytial Virus (RSV) G protein or a recombinant RSV G protein, as well as methods of their use and manufacture, are provided. The rB/HPIV3 vector comprises a genome comprising a heterologous gene encoding the RSV G protein or the recombinant RSV G protein. Nucleic acid molecules comprising the sequence of the genome or antigenome of the disclosed rB/HPIV3 vectors are also provided. The disclosed rB/HPIV3 vectors can be used, for example, to induce an immune response to RSV and HPIV3 in a subject.Type: GrantFiled: February 1, 2022Date of Patent: May 7, 2024Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter L. Collins, Ursula J. Buchholz, Bo Liang, Shirin Munir
-
Publication number: 20240139112Abstract: In an embodiment, the invention provides an isolated population of exosomes comprising interleukin-27 (IL-27) or interleukin-35 (IL-35). In an embodiment, the invention also provides a method of preparing a population of exosomes comprising interleukin-27 (IL-27), the method comprising: (a) isolating CD19+B2 cells or B1a cells; (b) activating the isolated cells with a LPS or a BCR agonist to provide activated cells; and (c) isolating exosomes secreted from the activated cells. In an embodiment, the invention also provides a method of preparing a population of exosomes comprising interleukin-35 (IL-35), the method comprising: (a) isolating CD138+plasma cells; (b) activating the isolated cells with a LPS or a BCR agonist to provide activated cells; and (c) isolating exosomes secreted from the activated cells. Additional embodiments of the invention are as described.Type: ApplicationFiled: May 28, 2021Publication date: May 2, 2024Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Charles E. Egwuagu, Minkyung Kang
-
Patent number: 11969466Abstract: Vaccines that elicit broadly protective anti-influenza antibodies. Some vaccines comprise nanoparticles that display HA trimers from influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to the stem region of an influenza HA protein. The fusion proteins self-assemble to form the HA-displaying nanoparticles. The vaccines comprise only the stem region of an influenza HA protein joined to a trimerization domain. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.Type: GrantFiled: May 8, 2023Date of Patent: April 30, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: John R. Mascola, Jeffrey C. Boyington, Hadi M. Yassine, Peter D. Kwong, Barney S. Graham, Masaru Kanekiyo
-
Publication number: 20240132619Abstract: Disclosed is a molecule comprising: (a) a first domain, which comprises a targeting moiety; (b) a second domain, which comprises an albumin binding domain (ABD), (c) a third domain, which comprises a furin cleavage sequence (“FCS”), which FCS is cleavable by furin; and (d) a fourth domain, which comprises an optionally substituted Domain III from Pseudomonas exotoxin A (“PE”). Related nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, methods of producing the molecule, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.Type: ApplicationFiled: September 19, 2023Publication date: April 25, 2024Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Ira H. Pastan, Junxia Wei, Masanori Onda, Tapan Bera, Mitchell Ho